...is never done.  However,  it doesn't stop us from pursuing sustainable innovation and thoughtful congruence with the needs of modern society. 

​

In 2019, the US Food & Drug Administration (FDA) granted Breakthrough Therapy Designation for studies of psilocybin in depressive disorders. Our efforts seek to enhance the adoption and support the efficacy of this type of worthy scientific research.

​

We at the Silly Siobahn family of companies will focus on the marriage of both beneficial and experiential elements of our products.

​

Can we rise above just having a clever name?  Can we become a trusted name that delivers products and services which change the world?

​

Our sleeves are rolled up and we're very engrossed in our work.  Stay tuned.

​

​

​

​